1	Multiplex PCR Assay to Detect High Risk Lineages of Salmonella Typhi and Paratyphi A				
2					
3	Fahad A Khokhar <sup>1</sup> , Derek DJ Pickard <sup>1</sup> , Zoe A Dyson <sup>1,2,3,4</sup> , Junaid Iqbal <sup>5</sup> , Agila K Pragasam <sup>6</sup> ,				
4	Jobin Jacob John <sup>6</sup> , Balaji Veeraraghavan <sup>6</sup> , Farah N Qamar <sup>5</sup> , Gordon Dougan <sup>1,7</sup> , Hilary				
5	MacQueen <sup>8</sup> , Sushila H Rigas <sup>8</sup> , Mark A Holmes <sup>9</sup> , Ankur Mutreja <sup>1,6</sup> *				
6					
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	<ol> <li>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, CB2 0AW, UK</li> <li>London School of Hygiene &amp; Tropical Medicine, London, WC1E 7HT, UK</li> <li>Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria, 3004, Australia</li> <li>Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1RQ, UK</li> <li>Department of Paediatrics and Child Health, Aga Khan University, Karachi, 74800, Pakistan</li> <li>Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India</li> <li>The Wellcome Trust, London, NW1 2BE, UK</li> <li>School of Life, Health &amp; Chemical Sciences, The Open University, Milton Keynes, MK7 6AA, UK</li> <li>Department of Veterinary Medicine, University of Cambridge, CB3 0ES, UK</li> </ol> *Correspondance: Dr. Ankur Mutreja, <u>am872@cam.ac.uk</u>				
22					
23	Abstract: Enteric fever infections remain a significant public health issue, with up to 20				
24	million infections per year. Increasing rates of antibiotic resistant strains have rendered many				
25	first-line antibiotics potentially ineffective. Genotype 4.3.1 (H58) is the main circulating				
26	lineage of S. Typhi in many South Asian countries and is associated with high levels of				
27	antibiotic resistance. The emergence and spread of extensively drug resistant (XDR) typhoid				
28	strains has increased the need for a rapid molecular test to identify and track these high-risk				
29	lineages for surveillance and vaccine prioritisation. Current methods require samples to be				

30 cultured for several days, followed by DNA extraction and sequencing to determine the

- 31 specific lineage. We designed and evaluated the performance of a new multiplex PCR assay,
- 32 targeting *S*. Paratyphi A as well as the H58 and XDR lineages of *S*. Typhi on a collection of
- 33 bacterial strains. Our assay was 100% specific for the identification of lineage specific S.

34	Typhi and S. Paratyphi A, when tested with a mix of non-Typhi Salmonella and non-
35	Salmonella strains. With additional testing on clinical and environmental samples, this assay
36	will allow rapid lineage level detection of typhoid of clinical significance, at a significantly
37	lower cost to whole-genome sequencing. To our knowledge, this is the first report of a SNP-
38	based multiplex PCR assay for the detection of lineage specific serovars of Salmonella
39	Typhi.
40	
41	Keywords: Salmonella; typhoid fever; Typhi; H58; XDR; Diagnostics; PCR
42	
43	Data Statement: All supporting data, code and protocols have been provided within the
44	article or through supplementary data files.
45	

#### 46 **INTRODUCTION**

47

Enteric fever is caused by the bacteria *Salmonella enterica* serovars Typhi and Paratyphi A, B and C. It remains a significant health issue, which is estimated to cause up to 20 million infections and 161,000 deaths per year, predominantly in low and middle-income countries in Southeast Asia and Africa. *S.* Typhi and *S.* Paratyphi A are human restricted pathogens and are transmitted by the faecal-oral route often via contaminated water (1). Vaccination, access to clean water, and improved sanitation are effective means to prevent transmission of typhoid.

55

56 Cases of typhoid fever can be treated with former first-line antibiotics such as 57 chloramphenicol, ampicillin or co-trimoxazole. However, the emergence of multi-drug 58 resistant (MDR) S. Typhi in the mid-1970s and the recent emergence of strains with 59 increased anti-microbial resistance (AMR) profiles to more antibiotics (2), has rendered these 60 treatment options potentially ineffective in the near future. Many MDR S. Typhi strains 61 possess self-transmissible incompatibility type (IncHI1) plasmids carrying a suite of 62 antimicrobial resistance genes. Haplotype 58 (H58) or genotype 4.3.1 is the dominant S. 63 Typhi lineage in many parts of Asia and Eastern Africa today and is associated with high 64 levels of multidrug resistance and reduced susceptibility to fluoroquinolones (2).

65

Extensively drug-resistant (XDR) *S*. Typhi, first reported in Pakistan in 2016 (3), was found to be an MDR H58 strain that had acquired an IncY plasmid from an *E. coli* isolate harbouring both *bla*CTX-M-15 and *qnrS* resistance genes conferring resistance to ceftriaxone and third generation cephalosporins. This leaves azithromycin as the only viable oral treatment option for XDR *S*. Typhi. However, recent reports of azithromycin-resistant *S*.

Typhi and *S.* Paratyphi A in Bangladesh (4) and Pakistan (5) have raised concerns about the
potential of this mutation to evolve in XDR strains in the future, further limiting treatment
options.

74

75 Current laboratory diagnosis of typhoid fever requires clinical samples to be sent to a 76 centralised laboratory to be processed by bacterial culture and standard identification, 77 followed by susceptibility, serological and/or advanced molecular tests such as real-time PCR 78 and whole-genome sequencing (WGS). Blood culture remains the diagnostic technique of 79 choice but takes several days for results and only identifies 45-70% of confirmed cases. It is 80 also limited by the low numbers of Salmonella bacteria in samples ranging from <1-22 81 organisms/ml of blood (6, 7). Sampling from bone marrow has been shown to have greater 82 sensitivity and specificity but that remains a highly invasive procedure. There have been 83 several studies that utilise PCR assays to identify invasive Salmonella serovars (8-14) but 84 rely on blood culture over 2-3 days followed by DNA extraction before PCR testing. More 85 recently, studies have shown that the use of ox bile-containing media for the enrichment of 86 bacteria directly from blood samples (15), or the selective removal of human DNA (16), 87 combined with a PCR assay can reduce the turnaround time for diagnosis and increase the 88 diagnostic sensitivity (17). Most importantly, however, is that none of the current routine 89 diagnostic platforms highlighted here offer a resolution to discriminate between low and 90 high-risk lineages in a single test.

91

92 In our study, we designed a simple, rapid, highly specific multiplex PCR assay for the 93 detection of *S*. Typhi, *S*. Paratyphi A, *S*. Typhi H58 and *S*. Typhi XDR, based on single 94 nucleotide polymorphisms (SNPs) specific for these lineages of clinical significance. Once

95 tested on clinical and environmental samples, this will be used to guide clinical and public

- 96 health decision making.
- 97

## 98 METHODS

99

#### 100 **DNA extraction and bacterial strains**

101 Bacterial isolates (Table 1) were cultured onto Luria-Bertani (LB) agar plates from frozen 102 stock vials. A single bacterial colony was picked to subculture into 1 ml of LB broth and 103 incubated overnight at 37°C in a shaking incubator. Genomic DNA was extracted from 104 overnight cultures using the Wizard Genomic DNA Purification Kit (Promega, USA). 105 Genomic DNA extracted from S. Typhi XDR strains was supplied by Aga Khan University, 106 Karachi, Pakistan. All DNA strains were diluted in 10 mM Tris buffer and quantified using 107 the Qubit 3 fluorometer with the dsDNA broad-range assay kit (Thermo Fisher Scientific, 108 UK). An additional 76 DNA samples were obtained for screening using our PCR assay, that 109 had been previously identified by Matrix-assisted laser desorption/ionization time-of-flight 110 mass spectrometry (MALDI-TOF MS) as S. Typhi or S. Paratyphi A. 111

- 112 **Table 1.** Bacterial DNA strains used in testing. All Salmonella strains are serovars of subspecies
- 113 *enterica* unless otherwise stated

Bacterial strain	Isolate details
S. Typhi BRD948	H10/15 Ty2 ( $\Delta aroC aroD htrA$ )
S. Typhi SGB87	98-0664 (H55)
S. Typhi	Quail strain
S. Typhi	lupe GEN0059 (4.1)
S. Typhi	403 Ty (H59 3.1.2)

S. Paratyphi A	AKU_12601
S. Paratyphi B	SPB7
S. Typhi H58	ERL12148
S. Typhi H58	ERL12960
S. Typhi XDR 1	
S. Typhi XDR 2	
S. Typhi XDR 3	
S. Typhi XDR 4	
S. Typhi XDR 5	
S. Enteritidis	PT4
S. Hadar	SC1
S. Infantis	SC31
S. Cholearasuis	SC-B67
S. enterica subsp. arizonae	CDC 346-86
S. enterica subsp. diarizonae	CDC 01-0005
S. Dublin	ТҮТ3627
S. Newport	E2002001708
<i>S</i> . 1,4, (5),12:i	CVM23701
S. Kentucky	CVM29188
S. Heidelberg	CVM30485
S. Javiana	CVM35943
S. Saint Paul	SARA29
S. Pullorum	S449/87
S. Typhimurium	D23580

S. Typhimurium	4/74
Esherichia coli	BL21
Vibrio cholerae	O1 El Tor

114

115

#### 116 Primer design

117 Primers targeting highly conserved genes were designed for the detection of S. Typhi and S. 118 Paratyphi A serovars (Table 2). Primers with additional mutations incorporated based on the 119 mismatch amplification mutation assay (MAMA) PCR principle as previously described (18), 120 were designed to selectively amplify a target sequence in the presence of a SNP of interest 121 for H58 and XDR lineages (19). All primers were designed using Primer-BLAST (20), 122 synthesised by Integrated DNA Technologies (IDT, USA) and were resuspended from their 123 lyophilised form in 10 mM Tris buffer. Appropriate amplicon lengths were selected for each 124 target with a minimum of 50 bp difference, in order to effectively separate and be visualised 125 by gel electrophoresis.

126

127 Table 2. Primer sequences used in our multiplex assay with expected amplicon sizes generated for128 each target.

Target   Primer nat		Primer sequence (5'-3')	Amplicon length (bp)
S. Typhi	ST_227F	GGCAGATATACTTTCGCAGGCA	227
	ST_227R	CCCAGAACCAAATTTGCTTACA	
S. Paratyphi A	SPA_305F	AGGGATGAGAATTTTCAGACGT	305
	SPA_305R	ACCCCAGCTCTGAGAGATATCT	
S. Typhi XDR	XDR_425F	TGAATGGTTCTGGTCTGGCG	425
	XDR_425R	CTAAACCACGACGGCTCAGT	

	H58_509F	GGGCTTGATGGCTTCATTAGT	
S. Typhi H58			509
	H58_509R	ACAGGTTGTACGCCTTTCCA	

129

#### 130 PCR protocol

131 Each PCR reaction contained 5 ng of DNA, 12.5 µl of 2X PCR Master Mix (Thermo Fischer 132 Scientific, UK), 8 or 10  $\mu$ M each of the forward and reverse primers (Table 1), and nuclease 133 free water to a final volume of 25  $\mu$ l. All reactions were performed on a T100 thermal cycler 134 (BioRad Laboratories Inc., USA) under the following cycling conditions; 95°C for 2 mins, 135 followed by 30 cycles of 95°C for 30 sec, 60°C for 45 sec, 68°C for 1 min, and final 136 extension at  $68^{\circ}$ C for 10 mins. The PCR products were run on 1.2% (w/v) agarose gels 137 containing SYBR® Safe DNA Gel Stain (Invitrogen, USA) and visualised on a ChemiDoc 138 MP imaging system (BioRad Laboratories Inc., USA).

139

## 140 **RESULTS**

141

Our multiplex assay not only distinguished *S*. Paratyphi A from *S*. Typhi, but also identified low and high-risk lineages of *S*. Typhi that are of clinical relevance (Figure 1). Optimal conditions were initially determined for singleplex PCR, before adapting for the multiplex reaction. The *S*. Typhi and *S*. Paratyphi A primers were designed from specific regions in their reference genomes that are highly conserved across all strains, genes STY0307 and SSPA2308 respectively. The *S*. Typhi and *S*. Paratyphi A specific primers yielded 227 bp and 305 bp amplicon products, respectively.

149

150 Through screening of our Typhi genome collection, we were able to determine SNPs which151 are specific to certain lineages, as detailed elsewhere (19, 21). These were chosen for use as

152 relevant diagnostic markers. Our marker for the multidrug resistant lineage 4.3.1 (H58) is 153 based on a C $\rightarrow$ T synonymous mutation (T349T) in the STY2513 gene at position 2348902 in 154 the S. Typhi CT18 reference genome, which encodes for the anaerobic glycerol-3-phosphate 155 dehydrogenase subunit A (glpA) gene. This mutation covers all H58 4.3.1 lineage and sub-156 lineage isolates, with our primers generating a 509 bp sized amplicon product. The diagnostic 157 marker for the XDR lineage (genotype 4.3.1.1.P1) is based on a  $G \rightarrow A$  (E13E) synonymous 158 mutation in the STY0962 gene encoding anaerobic dimethyl sulfoxide reductase chain A 159 precursor (dmsA), at position 955875 of the CT18 genome. Our XDR primers targeting this 160 SNP generate an amplicon size of 425 bp. Figure 2 shows the results of the multiplex assay 161 visualised by gel electrophoresis. Pairwise alignments to the CT18 reference sequence with 162 our H58 and XDR SNPs are summarised in Figure 3 below.

163

Our results showed that our initial primers designed for the H58 and XDR targets with just the one SNP incorporated were not specific for these lineages as they were binding to other *S*. Typhi strains (data not shown). Further adaptation was made by incorporating an additional SNP at the 3' end of the primer which induced the specificity for the target sequence and strain and subsequently produced no false positive results (Figure 3). To determine the specificity of the assay, we tested the multiplex primers on a range of non-Typhi *Salmonella* and non-*Salmonella* pathogens, which showed no amplification.

171

From the additional DNA samples obtained for testing, 75/76 were originally identified as *S*. Typhi, with the remaining isolate identified as *S*. Paratyphi A. Using the same PCR conditions listed above, we tested our assay on these samples, with the single *S*. Paratyphi A sample confirmed by producing only a single 305 bp band as expected. Interestingly, 13/75 isolates that had previously been identified as *S*. Typhi, only produced the 305 bp *S*.

177	Paratyphi A band in our assay. To investigate these discrepant results, the isolates were later
178	whole-genome sequenced and confirmed as S. Paratyphi A. Of the remaining isolates, our
179	PCR assay identified 54/76 as S. Typhi H58, 4/76 as S. Typhi non-H58/non-XDR, 1/76 as
180	mixed S. Typhi and S. Paratyphi A, and 4/76 did not produce any bands (data not shown).
181	None of these additional 76 DNA isolates were identified as S. Typhi XDR.

182

#### 183 **DISCUSSION**

184

185 Typhoid fever remains a major public health issue particularly in South and Southeast Asia. 186 Early diagnosis is important for detecting cases in patients but also to discover sources of 187 potential outbreaks. It is widely accepted that improved methods for the diagnosis and 188 monitoring of the emergence and spread of S. Typhi would facilitate disease control and 189 treatment. Yet there remain difficulties in obtaining sufficient samples for rapid molecular 190 testing as direct blood samples are limited by the low abundance of Salmonella bacteria and 191 other sampling methods remain extremely invasive and not widely available. Standard 192 diagnostic techniques also lack the resolution to discriminate between different servors of S. 193 Typhi as well as drug-susceptible from drug-resistance strains. An ideal diagnostic for 194 typhoid fever should be high-resolution, rapid, specific, and sensitive for the target organism. 195

The widespread dissemination of the H58 lineage in multiple countries, XDR lineage across Pakistan, and the emergence of azithromycin resistant isolates is of concern. The only method to identify and track the spread of such resistant strains is by whole genome sequencing. Based on our SNP-based diagnostic assay, there is potential to design and incorporate PCR primers as an additional target to monitor the spread of such strains at a significantly lower cost compared to complete genome sequencing.

202

203 Our multiplex PCR assay for the detection of S. Typhi and S. Paratyphi A enables the 204 identification of the MDR H58 and XDR S. Typhi lineages. In many countries, S. Paratyphi 205 A infections are increasingly common, so it was important that this assay could distinguish its 206 presence in a population (22). Our single and multiplex PCR assays found no false positive 207 reaction with non-Typhi serotypes or non-Salmonella pathogens, suggesting that the target 208 genes are specific for our Salmonella serovar targets. From the additional DNA samples 209 obtained, our assay was able to correctly identify S. Paratyphi A isolates that had previously 210 been classified as S. Typhi by MALDI-TOF MS, which were subsequently confirmed as S. 211 Paratyphi A by whole-genome sequencing. Although our assay was able to positively identify 212 XDR S. Typhi from extracted DNA from five samples, we acknowledge there is a lack of 213 additional XDR isolates in our collection. A further limitation is that our experiments were 214 performed using DNA extracted from purified cultures and therefore contained few potential 215 PCR inhibitors. Further optimisation of our PCR assay is planned for working directly on 216 bacterial colonies in addition to sampling from environmental water and sewage samples. As 217 direct assays are developed for clinical use in the future, our PCR assay should directly plug 218 in to obtain the lineage level resolution.

219

We envision that our multiplex PCR assay will be widely used in routine laboratory diagnosis from DNA extracted after blood culture incubation, and eventually in combination with previously mentioned enrichment methods. Having a low cost, high-resolution, simple PCR test, as opposed to the current expensive whole-genome sequencing methods, allows our assay to be accessible to low- and middle-income countries where improved diagnostics for typhoid fever are most needed. The lineage level rapid detection of *S*. Typhi will make clinical decision making more efficient and help tackle AMR.

#### 227

# 228 Funding information

- 229 This study was funded by a Bill & Melinda Gates Foundation grant to M.A.H. and A.M., and the National
- 230 Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University
- 231 Hospitals NHS Foundation Trust, AMR theme].

232

#### 233 Author contributions

- 234 Conceptualisation and Funding Acquisition: A.M., M.A.H., G.D.; Investigation, Methodology and
- 235 Visualisation: F.K. and D.J.J.P. Writing Original Draft Preparation: F.K., D.J.J.P., M.A.H., A.M.;
- 236 Writing Review and Editing: all authors.
- 237

## 238 **Conflicts of interest**

239 The authors declare that there are no conflicts of interest.

# 240 **REFERENCES**

- 241
- 242 1. Typhoid fever: World Health Organisation; [cited 2020 November]. Available from: 243 http://www.emro.who.int/health-topics/typhoid-fever/. 244 2. Park SE, Pham DT, Boinett C, Wong VK, Pak GD, Panzner U, et al. The 245 phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa. 246 Nature Communications. 2018;9(1). 247 3. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of 248 an Extensively Drug-Resistant Salmonella enterica Serovar Typhi Clone Harboring a 249 Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation 250 Cephalosporins. mBio. 2018;9(1):e00105-18. 251 Hooda Y, Sajib MSI, Rahman H, Luby SP, Bondy-Denomy J, Santosham M, et al. 4. 252 Molecular mechanism of azithromycin resistance among typhoidal Salmonella strains in 253 Bangladesh identified through passive pediatric surveillance. PLOS Neglected Tropical 254 Diseases. 2019;13(11):e0007868. 255 5. Iqbal J, Dehraj IF, Carey ME, Dyson ZA, Garrett D, Seidman JC, et al. A Race 256 against Time: Reduced Azithromycin Susceptibility in Salmonella enterica Serovar Typhi in 257 Pakistan. mSphere. 2020;5(4). 258 6. Parry CM, Wijedoru L, Arjyal A, Baker S. The utility of diagnostic tests for enteric 259 fever in endemic locations. Expert Review of Anti-infective Therapy. 2011;9(6):711-25. 260 7. Hosoglu S, Wain J. The laboratory diagnosis of enteric fever. The Journal of Infection 261 in Developing Countries. 2008;2(06). 262 Nasrummassi M. Quantitative detection of serovar Typhi from blood of suspected 8. 263 typhoid fever patients by real-time PCR. International Journal of Medical Microbiology. 264 2005;295(2):117-20. 265 9. Levy H, Diallo S, Tennant SM, Livio S, Sow SO, Tapia M, et al. PCR Method To 266 Identify Salmonella enterica Serovars Typhi, Paratyphi A, and Paratyphi B among 267 Salmonella Isolates from the Blood of Patients with Clinical Enteric Fever. Journal of 268 Clinical Microbiology. 2008;46(5):1861-6. 269 10. Song JH, Cho H, Park MY, Na DS, Moon HB, Pai CH. Detection of Salmonella typhi 270 in the blood of patients with typhoid fever by polymerase chain reaction. Journal of Clinical 271 Microbiology. 1993;31(6):1439-43. 272 Massi MN, Gotoh A, Bishnu A, Kawabata M, Shirakawa T, Gotoh A, et al. Rapid 11. 273 diagnosis of typhoid fever by PCR assay using one pair of primers from flagellin gene of Salmonella typhi. Journal of Infection and Chemotherapy. 2003;9(3):233-7. 274 275 Chaudhry R, Laxmi BV, Nisar N, Ray K, Kumar D. Standardisation of polymerase 12. 276 chain reaction for the detection of Salmonella typhi in typhoid fever. Journal of Clinical 277 Pathology. 1997;50(5):437-9. 278 Nga TVT, Karkey A, Dongol S, Thuy HN, Dunstan S, Holt K, et al. The sensitivity of 13. 279 real-time PCR amplification targeting invasive Salmonellaserovars in biological specimens. 280 BMC Infectious Diseases. 2010;10(1):125. 281 14. Sajib MSI, Tanmoy AM, Hooda Y, Rahman H, Andrews JR, Garrett DO, et al. 282 Tracking the Emergence of Azithromycin Resistance in Multiple Genotypes of Typhoidal 283 Salmonella. mBio. 2021;12(1). 284 15. Zhou L, Pollard AJ. A fast and highly sensitive blood culture PCR method for clinical 285 detection of Salmonella enterica serovar Typhi. Annals of Clinical Microbiology and 286 Antimicrobials. 2010;9(1):14.

- 287 16. Zhou L, Pollard AJ. A novel method of selective removal of human DNA improves
- PCR sensitivity for detection of Salmonella Typhi in blood samples. BMC Infectious
  Diseases. 2012;12(1):164.
- 290 17. Neupane DP, Dulal HP, Song J. Enteric Fever Diagnosis: Current Challenges and
  291 Future Directions. Pathogens. 2021;10(4):410.
- 292 18. Morita M, Ohnishi M, Arakawa E, Bhuiyan NA, Nusrin S, Alam M, et al.
- 293 Development and validation of a mismatch amplification mutation PCR assay to monitor the
- dissemination of an emerging variant of Vibrio choleraeO1 biotype El Tor. Microbiology and
   Immunology. 2008;52(6):314-7.
- 296 19. Dyson ZA, Holt KE. Five years of GenoTyphi: updates to the global Salmonella
  297 Typhi genotyping framework. J Infect Dis. 2021.
- 298 20. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST:
  299 A tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics.
- 300 2012;13(1):134.
- 301 21. Wong VK, Baker S, Connor TR, Pickard D, Page AJ, Dave J, et al. An extended
- 302 genotyping framework for Salmonella enterica serovar Typhi, the cause of human typhoid.
- 303 Nat Commun. 2016;7:12827.
- 304 22. Bhetwal A, Maharjan A, Khanal PR, Parajuli NP. Enteric Fever Caused bySalmonella
- 305 entericaSerovars with Reduced Susceptibility of Fluoroquinolones at a Community Based
- 306 Teaching Hospital of Nepal. International Journal of Microbiology. 2017;2017:1-6.
- 307



M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17



18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 M

Α	2,348,880	2,348,888		2,34	48,902	2,348,914
S. Typhi CT18	ACGGC	CTTGAT	GGCT	TCATTAC	CATT	ACCGGCGGG
H58_509F S. Typhi H58	GGG ACGGG	ICTTGAT ICTTGAT	GGCT GGCT	TCATTA <mark>G</mark> TCATTAC	ΑΤΤ	ACCGGCGGG
В	955,866	955	,875	955,883		955,900
S. Typhi CT18	GGC	AGCCGA	GG <mark>T</mark> GA	GCCGTCG	TGGT	TTAGTCAAAA
Complement (3' → 5'	) CCC	<b>TCGGCT</b>	CCACT	CGGCAGC	ACCA	AATCAGTTTT
XDR_425R (3' → 5') S. Typhi XDR	CCC	TCGGCT	GACT CACT	CGGCAGC	ACCA ACCA	AATC AATCAGTTTT